<DOC>
	<DOCNO>NCT02777242</DOCNO>
	<brief_summary>Evaluation safety tolerability testosterone enanthate ( TE ) follow single dose via QuickShotÂ® Testosterone ( QST ) 50 mg , 75 mg , 100 mg administer intend user usability study .</brief_summary>
	<brief_title>Subcutaneous Testosterone Enanthate Safety Adult Men Diagnosed With Hypogonadism</brief_title>
	<detailed_description>Intended user patient well patient caregiver , family member friends able assist patient administer medication ( i.e . lay user ) . One user group approximately 15 patient dose administer qualified healthcare professional ( HCP ) .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow criterion screen participate study : 1 . The patient 18 year age old ; 2 . The patient speaks , read , understand English language sixth grade read level high ; 3 . The patient willing photograph take and/or video record completes study task , deidentified prior potential use image ( ) scientific educational purpose ; 4 . The patient sufficient availability participate study comply study schedule ; 5 . The patient transportation study site ; 6 . The patient demonstrate ability understand willingness follow study instruction ; 7 . The patient read , state understands , sign Informed Consent Form ( ICF ) . 8 . The patient diagnose hypogonadism ; 9 . The patient male ; 10 . The patient document history hypogonadism . Diagnosis must include documentation consistent sign symptom androgen deficiency ; 11 . Patients good health determine Investigator base medical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory test ; 12 . All male patient must practice effective contraception study 30 day receive last dose study drug . Acceptable method birth control include condom spermicide , vasectomy , monogamous relation female partner non childbearing potential ( postmenopausal , surgical , congenital sterility ) child bear potential practicing reliable method contraception ( hormonal contraception , double barrier method spermicide , intrauterine device ) ; 13 . Patients must ability provide write informed consent comply study requirement restriction include study visit schedule . Exclusion Criteria Patients exclude participation study follow criterion apply : 1 . Failure meet 1 Inclusion Criterion ; 2 . The patient participate interview , focus group , study medical product therapy within past 3 month prior QST autoinjector usability study , clinical trial , and/or previous exposure investigational device ; 3 . The patient someone live work work Marketing/Market Research Company , pharmaceutical medical device company , manufacturer , distributor , wholesaler nonprescription drug product , government health agency ; 4 . Individuals allergic reaction idiosyncratic reaction sesame seed , sesame product , and/or sesame oil ; 5 . History food anaphylaxis ; 6 . History intolerance , allergy , idiosyncratic reaction testosterone product ; 7 . Unstable psychiatric illness ; 8 . Lifetime history psychosis , suicidal behavior , bipolar disorder , personality disorder ; active suicidal ideation within 6 month prior screen ; inadequately treat depression . Note : Patients depression adequately treat stable response 3 month may admit study Investigator 's discretion ; 9 . Body mass index 40 kg/m2 ; 10 . Hematocrit 52 % Initial Screening Visit ; 11 . Individual history current evidence breast prostate cancer ; 12 . Other malignancy diagnose treat within 5 year date Initial Screening Visit exception nonmelanoma carcinoma skin ; 13 . Elevated prostatespecific antigen ( PSA ) age . Prostatespecific antigen 2.5 ng/mL men 18 60 year old 4 ng/mL men 61 year old exclusionary ; 14 . Presence prostate nodule induration upon digital rectal exam ; 15 . Obstructive uropathy prostatic origin severity , opinion Investigator , contraindicate use testosterone ; 16 . Patients poorly control diabetes . Patients stable dose regimen anti diabetic medication minimum 4 week , hemoglobin A1c level 7.5 % may participate study ; 17 . Patients New York Heart Association Class III IV congestive heart failure ; 18 . Within 6 month Initial Screening Visit , myocardial infarction , unstable angina lead hospitalization , percutaneous coronary intervention , coronary artery bypass graft , uncontrolled cardiac arrhythmia , stroke transient ischemia attack , carotid revascularization , endovascular procedure , surgical intervention peripheral vascular disease ; 19 . History , current treatment , thromboembolic disease current use anti thromboembolic medication . Use lowdose aspirin permit routine cardioprophylaxis ; 20 . Patients intermittently take adrenocorticotropic hormone , oral , depot corticosteroid ( ongoing regimen require panhypopituitarism adrenal failure permit ) ; 21 . Untreated sleep apnea ; 22 . Historical current evidence clinically significant disease disorder , judgment Investigator , may cause participation study detrimental patient may influence result study . This include cardiovascular , renal , hepatic , hematological , endocrine , gastrointestinal , pulmonary disease ; 23 . Positive serology human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C virus antibody Initial Screening Visit ; 24 . Current evidence alcohol drug abuse . A positive drug screen exclusionary without documentation current prescription medical condition require treatment drug screen positive . Exception : tetrahydrocannabinol allow state recreational use marijuana legal ; 25 . Any skin condition could confound injection site assessment ( eg , dermatographism , urticaria , atopic dermatitis ) . Tattoos , scar , psoriasis injection site prohibit ; 26 . Administration investigational compound within 1 month prior Initial Screening Visit 5 halflives investigational product ( whichever longer ) ; 27 . Patients consider schedule undergo major surgery dental procedure anticipate associated significant blood loss ( 500 mL ) study ; 28 . Systolic blood pressure ( SBP ) 140 mmHg and/or diastolic blood pressure ( DBP ) 90 mmHg Initial Screening Visit . Patients treated hypertension SBP 140 and/or DBP 90 mmHg Initial Screening Visit must stable dose antihypertensive medication least 14 day Day 1 ( Baseline Visit ) plan remain dose throughout duration study ; 29 . Unable understand verbal write English language certify translation inform consent available .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone enanthate</keyword>
</DOC>